Artrya Limited (ASX: AYA), a commercial-stage medical technology company leveraging advanced imaging and artificial intelligence to transform the assessment of coronary artery disease, has reported a widened loss for the financial year ended 30 June 2026. The company posted a loss from ordinary activities after tax attributable to owners of $25,183,000, an increase of 53.5% from the $16,406,000 loss recorded in the previous corresponding period. Basic and diluted earnings per share were both ($16.97) cents, an improvement from ($17.77) cents in the prior year. The company did not declare any dividends for the period.
Despite the increased loss, Artrya’s revenues from ordinary activities remained flat at $28,000. This figure is influenced by a non-cash impact of $149,000 related to foundation partner affiliate options, with underlying SaaS revenue reaching $177,000 compared to $28,000 in the prior year. The company marked its first full year of commercial operations by successfully integrating its Salix® platform and securing initial U.S. customers, including Tanner Health, Northeast Georgia Health System, and Cone Health, laying the groundwork for recurring revenue.
Key operational milestones included securing FDA clearance for the Salix® Coronary Plaque module, complementing the earlier clearance for Salix® Coronary Anatomy. This enables subscription-based software revenues and fee-per-scan reimbursement opportunities. Artrya also initiated the SAPPHIRE Study to generate clinical evidence and strengthen its U.S. market presence. Financially, the company bolstered its balance sheet with an $80 million capital raise, contributing to a cash balance of $44.0 million (up from $11.3 million) and net tangible assets per ordinary security increasing to 45.30 cents from 14.61 cents. The company’s financial statements received an unmodified audit opinion.
